CASE REPORT

Unusual presentation of small bowel GIST: diffuse omental & mesenteric sarcomatosis

Marco Catarci1,*, Andrea Balla2 and Luigi Coppola3

1General Surgery Unit, “C. & G. Mazzoni” Hospital, Ascoli Piceno, Italy, 2General Surgery Unit, “San Paolo” Hospital, Civitavecchia, Rome, Italy and 3Pathology Unit, “S. Pertini” Hospital, Rome, Italy

*Correspondence address. Ospedale “C. e G. Mazzoni”—ASUR Marche AV5, Via degli Iris snc; 63100 Ascoli Piceno, Italy. Tel: +39 3298610040; Fax: +39 0736358749; E-mail: marco.catarci@sanita.marche.it

Abstract

Gastrointestinal stromal tumors (GISTs) represent ~1% of gastrointestinal (GI) tract neoplasms. Unusual presentation of a small bowel GIST with diffuse omental and mesenteric implants in a symptomatic patient is reported. CT scan in a 68-years-old woman showed multiple processes with solid density and colliquation areas in the abdominal cavity. At surgery, an uncommon finding of multiple omental and mesenteric secondary implants was evident. The index mass with 40 cm of adjacent small bowel, omentum and all peritoneal lesions were completely removed. Definitive pathology report showed a small bowel GIST with focal areas of necrosis and high mitotic activity (35 mitosis/50 High Power Fields), with multiple metastases on mesentery and omentum. Patient was therefore submitted to adjuvant treatment with Imatinib and a close follow-up program. Small bowel GIST with high mitotic activity may present with diffuse omental and mesenteric peritoneal seedings. Complete surgical clearance remains the mainstay of treatment.

INTRODUCTION

Gastrointestinal stromal tumors (GISTs) represent the most common mesenchymal neoplasm of the gastrointestinal (GI) tract [1, 2]. Common GIST locations are the stomach (50–60%) followed by the small bowel (20–30%) and the esophagus, colon and rectum [3]. GISTs can have atypical location in the omentum or in other sites as mesentery, retroperitoneum, gallbladder, abdominal wall, peri vesical tissue, pharynx, mediastinum, liver and pancreas [4], being defined as extra-gastrointestinal stromal tumors (EGISTs).

Being asymptomatic in 70% of cases, GISTs are often an incidental finding [2]. Nonspecific symptoms as well as nausea, vomiting, abdominal discomfort, weight loss or more severe conditions such as bleeding (haematemesis, melena or anemia), rupture of the tumor (acute abdomen), dysphagia and bowel or biliary obstruction are also described [2].

GISTs tumor cells express the tyrosine kinase KIT receptor (CD117), because of a mutation in the proto-oncogene c-kit, or another tyrosine kinase receptor such as the platelet-derived growth factor receptor alpha oncogene (PDGFRα) [1–3]. We report an unusual presentation of a small bowel GIST with diffuse omental and mesenteric implants in a symptomatic patient treated by surgical complete removal of the mass, omentum and metastases.

CASE REPORT

A 68-years-old woman (body mass index 35.6) was admitted with recent onset sideropenic anemia and not heart-related angina pectoris. At physical examination, a slightly mobile mass in the left iliac fossa was palpable. Carcinoembryonicantigen, carbohydrate antigen 19.9 (CA 19.9) carcinoma antigen 125 (CA 125) were normal. Upper and lower GI endoscopy were negative for any lesion. The patient was submitted for computed tomography (CT) scan, showing multiple solid density processes with colliquation areas in the abdominal cavity (Fig. 1). The greatest...
mass (8.0 × 5.6 cm) was located in the pelvis in close contact with the uterine fundus and the small bowel (Fig. 2). Cranially to this process, at least 20 other tumors with a diameter between 0.8 and 3.8 cm could be appreciated.

After multidisciplinary team discussion, patient was submitted to diagnostic laparoscopy. Intra-operatively, a friable and easily bleeding bulky pelvic mass was found (∼5 × 8 cm), originating from the free margin of an ileal loop without infiltration of uterus and ovaries. Multiple secondary omental and mesenteric lesions were confirmed. A midline laparotomy was therefore performed, showing multiple omental and mesenteric secondary implants (Fig. 3) and a bulky pelvic mass originating from the small bowel (Fig. 4). Omentectomy, small bowel resection and complete removal of all mesenteric implants were performed. Postoperative course was uneventful with discharge on postoperative Day 6.

Definitive pathology, according to Miettinen [4], showed a small bowel GIST with focal areas of necrosis and high mitotic activity (35 mitosis/50 HPF). Immunohistochemistry was positive for CD117, DOG1, CD34 and negative for S100 and smooth muscle actin. Ten metastases on the small bowel mesentery and various others on the omentum were also reported. After oncological counseling, patient was submitted to adjuvant treatment with Imatinib mesylate 800 mg twice daily of and a close follow-up program, remaining disease-free after 24 months.

DISCUSSION

GISTs are common mesenchymal neoplasms with a predominance in elderly patients (median age 66–69 years), such as in this report [2]. Familial or sporadic GISTs are both described but often no differences are observed in phenotypic and molecular features [2]. In case of small lesions, GISTs appear at contrast enhanced CT scan as a solid soft mass with heterogeneous enhancement; larger tumors and/or large exophytic grows may be due more difficult to diagnose due to necrosis, hemorrhage and degenerating elements. Small bowel GISTs may present as an incidental finding on abdominal imaging, but are often large at diagnosis, and they more commonly present with ulceration and bleeding (occult or massive). Other common presenting
CONCLUSIONS

GIST is often considered a low malignancy tumor due to the asymptomatic course of the disease in the majority of cases. Anyway, delay in diagnosis can lead to clinical presentation when the tumor is already metastatic. In case of omental and mesenteric spread, whenever possible, surgery remains the best first line of treatment. Alternatively, imatinib mesylate can be employed in a neo-adjuvant setting to reduce the tumor load before surgery.

REFERENCES

1. Yacob M, Inian S, Sudhakar CB. Gastrointestinal stromal tumours: review of 150 cases from a single Centre. Indian J Surg 2015;77:505–10.
2. Watson GA, Kelly D, Melland-Smith M, Gleeson J, McEntee G, Kelly CM, et al. Get the GIST? An overview of gastrointestinal stromal tumours. Ir J Med Sci 2016;185:319–26.
3. Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors presenting as omental masses–a clinicopathologic analysis of 95 cases. Am J Surg Pathol 2009;33:1267–75.
4. Miettinen M, Makhlouf H, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol 2006;30:477–89.
5. Oei TN, Jagannathan JP, Ramaiya N, Ros PR. Peritoneal sarcomatosis versus peritoneal carcinomatosis: imaging findings at MDCT. AJR Am J Roentgenol 2010;195:W229–35.
6. Miettinen M, Lasota J. Gastrointestinal stromal tumours – definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001;438:1–12.
7. Demetri GD, Benjamin RS, Blanke CD, Blay JY, Casali P, Choi H, et al. NCCN task force report: management of patients with gastrointestinal stromal tumor (GIST)–update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw 2007;5:S1–S29.
8. Otani Y, Furukawa T, Yoshida M, Saikawa Y, Wada N, Ueda M, et al. Operative indications for relatively small (2-5 cm) gastrointestinal stromal tumor of the stomach based on analysis of 60 operated cases. Surgery 2006;139:484–92.
9. Miettinen M, Lasota J. Gastrointestinal stromal tumours: pathology and prognosis at different sites. Semin Diagn Pathol 2006;23:70–83.
10. Emory TS, Sobin LH, Lukes I, Lee DH, O’Leary TJ. Prognosis of gastrointestinal smooth muscle (stromal) tumours: dependence on anatomic site. Am J Surg Pathol 1999;23:82–7.

CONFLICT OF INTEREST STATEMENT

None declared.

FUNDING

None.